

Applicant: Erik Buntinx
Serial No. 10/752,423
Filed: January 6, 2004
page 2 of 2

REMARKS

Claims 1-4, 6-15 and 17-63 are pending in the subject application.

In the June 20, 2007 Office Action, the Examiner required that applicant make an election of claims to pursue in the application together with election of species.

In response to the restriction requirement, applicant hereby elects Group I, i.e., Claims 1-10, drawn to a method of treating a disease or disorder with an underlying dysregulation of emotional functionality comprising administering to a patient a compound having (i) selective affinity for the dopamine (D4) receptor and a (ii) selective affinity for the 5-HT2A receptor.

With respect to the species election, applicant elects (a) anxiety disorders for a species of disorder and (b) pipamperone for a species of compound.


Claims 1-4 and 6-10 are readable upon the elected invention.

No fee is deemed necessary in connection with the submission of this Communication. However, if any fee is required to maintain the pendency of the subject application, authorization is hereby given to withdraw the amount of any such fee from Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP
Attorneys for Applicant
New York, New York 10016
(212) 336 8000

Dated: July 10, 2007
New York, New York

By 
Alan D. Miller, Reg. No. 42,889